SGO 2019: TWiST Backs Benefits of PARP Inhibitor in Ovarian Cancer

The TWiST analysis of the phase III ENGOT-OV16/NOVA trial evaluated the time without symptoms or toxicity for niraparib vs placebo in patients with recurrent ovarian cancer.

Source: CancerNetwork - March 21, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news